What is Disposable Insulin Pen Market?
Insulin which is produced by pancreas is a hormone that controls diabetes. The insulin pen is equipment which injects insulin into diabetic patient for the treatment of diabetes. It consists of a cartridge and a dial for measurement of dose. These are also used with disposable pen needle for injecting the dose. The insulin pens are easier to use, convenient and have improved medication adherence These advantages over vial and syringe deliveries are increasing the demand among diabetic patients which is fueling the market growth.
The market study is being classified and major geographies with country level break-up.
StraZeneca (United Kingdom), Teruma Medical Corporation (Japan), Greinier Bio One International GmBH (United States), F. Hoffman La Roche AG (Switzerland), Becton, Dickinson and Company (United States), Bayer Cropscience Ltd. (Germany), HTL STREFA SA (Poland), Becton Dickinson (United States), Novo Nordisk (Denmark) and Sanofi-aventis (France) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Owen Mumford (United Kingdom), Wockhardt (India) and Phillips-Medisize (United States).
The global Disposable Insulin Pen market is witnessing rise in competitiveness among the players. In terms of market share, the major players are currently dominating the market. However, with increasing innovations in technology, some of the companies are increasing the market presence by securinf new contracts and tapping new markets Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Disposable Insulin Pen market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Disposable Insulin Pen market by Type, Application and Region.
On the basis of geography, the market of Disposable Insulin Pen has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increase in Number of Diabetic Patients across the World
- Features Such As Convenience and Easy to Use is Fuelling the Market
Market Trend
- Continuous Advancements in Insulin Pen and Other Equipment
- Changing Lifestyle of Individuals
Restraints
- Availability of Alternative Technique Such as Insulin Pumps, Injection Ports
Opportunities
- Rising Research and Development Activities for Diabetes Disease
- Increasing Investments in Healthcare Infrastructure
Challenges
- Lack of Awareness about the Insulin Pen
Market Leaders and some development strategies
On 25th February 2019, Roche has entered into the agreement to acquire Spark Therapeutics which is committed to discover, develop and deliver the gene therapies.
On 23rd October 2018, Novo Nordisk has launched two connected insulin pens which are named NovoPen 6 and NovoPen Echo Plus. These connected pens will help the patients to track the trend in insulin.
Key Target Audience
Manufacturers, Raw material suppliers, Government associations, Research organizations, Enterprise software vendors and Others